{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T06:27:40Z","timestamp":1762928860812,"version":"3.41.2"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR130-P19"],"award-info":[{"award-number":["TRR130-P19"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Pemphigus diseases are rare, and the treatment response differs between patients. Several therapy changes are often required to achieve disease control and avoid unwanted side effects. We aimed to analyze the treatment courses of pemphigus patients and the clinical responses regarding therapy changes. Pemphigus patients in our center were retrospectively examined according to the medication and dosage, disease activity, reason for treatment changes, and autoantibody concentrations. Therapy changes due to insufficient therapeutic effects or side effects were analyzed. Seventy-seven pemphigus patients with repeated consultations were identified (81% pemphigus vulgaris, 19% pemphigus foliaceus). Disease control was achieved in 66 patients (86%; score \u201calmost clear\u201d or \u201cclear\u201d), with an average of 4 different therapy regimens (range 1\u201318 changes), after an average of 2 years of treatment (range 0\u201311 years). Twenty-two patients (29%) with refractory disease received rituximab, of which 19 (86%) subsequently achieved remission. Anti-desmoglein-1 and\u22123 concentrations correlated with disease severity, but not with the number of treatment changes. The identification of an effective and safe therapy for the individual pemphigus patient is a challenge and often requires time, which is reflected by a high number of therapy changes. Predictive parameters are warranted to directly identify the safest and most efficient treatment regimen for an individual patient.<\/jats:p>","DOI":"10.3389\/fmed.2020.581820","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T09:34:55Z","timestamp":1606296895000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapy Changes During Pemphigus Management: A Retrospective Analysis"],"prefix":"10.3389","volume":"7","author":[{"given":"Roberta","family":"Scarpone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Francuzik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margitta","family":"Worm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Heine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"CD006263","DOI":"10.1002\/14651858.CD006263.pub2","article-title":"Interventions for pemphigus vulgaris and pemphigus foliaceus","volume":"1","author":"Martin","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/ddg.14097_g","article-title":"S2k-Leitlinie zur Therapie des Pemphigus vulgaris\/foliaceus und des bullosen Pemphigoids: 2019 Update","volume":"18","author":"Schmidt","year":"2020","journal-title":"J Dtsch Dermatol Ges."},{"key":"B4","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.clindermatol.2013.01.004","article-title":"Pemphigus: etiology, pathogenesis, and inducing or triggering factors: facts and controversies","volume":"31","author":"Ruocco","year":"2013","journal-title":"Clin Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/1346-8138.12486","article-title":"Japanese guidelines for the management of pemphigus","volume":"41","author":"Amagai","year":"2014","journal-title":"J Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/jdv.12772","article-title":"Pemphigus. S2 Guideline for diagnosis and treatment\u2013guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)","volume":"29","author":"Hertl","year":"2015","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fmed.2019.00259","article-title":"Pemphigus vulgaris: short time to relapse in patients treated in a Danish Tertiary Referral Center","volume":"6","author":"Mohamad","year":"2019","journal-title":"Front Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/TCRM.S142471","article-title":"Emerging treatment options for the management of pemphigus vulgaris","volume":"14","author":"Kridin","year":"2018","journal-title":"Ther Clin Risk Manag."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/bjd.14463","article-title":"Comorbidities and inpatient mortality for pemphigus in the U.S.A","volume":"174","author":"Hsu","year":"2016","journal-title":"Br J Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/jid.2011.249","article-title":"Incidence, mortality, and causes of death of patients with pemphigus in Taiwan: a nationwide population-based study","volume":"132","author":"Huang","year":"2012","journal-title":"J Invest Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"a180","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris\u2013incidence and mortality in the UK: population based cohort study","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1056\/NEJMc1508234","article-title":"Long-term remissions in recalcitrant pemphigus vulgaris","volume":"373","author":"Ahmed","year":"2015","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"676","DOI":"10.2340\/00015555-2046","article-title":"Low-dose anti-thymocyte globulin inhibits human B-cell differentiation into antibody-secreting cells","volume":"95","author":"Klaus","year":"2015","journal-title":"Acta Derm Venereol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/archdermatol.2009.9","article-title":"ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus","volume":"145","author":"Abasq","year":"2009","journal-title":"Arch Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1046\/j.1365-2133.2002.04838.x","article-title":"Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3","volume":"147","author":"Cheng","year":"2002","journal-title":"Br J Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1046\/j.1365-2133.2001.04132.x","article-title":"The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels","volume":"144","author":"Harman","year":"2001","journal-title":"Br J Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1001\/archderm.135.2.143","article-title":"Desmoglein 3-ELISA: a pemphigus vulgaris-specific diagnostic tool","volume":"135","author":"Lenz","year":"1999","journal-title":"Arch Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1600-0625.2010.01069.x","article-title":"Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serumautoantibody levels in individual pemphigus patients","volume":"19","author":"Schmidt","year":"2010","journal-title":"Exp Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1684\/ejd.2007.0090","article-title":"Introducing a novel autoimmune bullous skin disorder intensity score (ABSIS) in pemphigus","volume":"17","author":"Pfutze","year":"2007","journal-title":"Eur J Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1172\/JCI65938","article-title":"T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies","volume":"123","author":"Hess","year":"2013","journal-title":"J Clin Invest."},{"key":"B23","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nri1886","article-title":"Competence and competition: the challenge of becoming a long-lived plasma cell","volume":"6","author":"Radbruch","year":"2006","journal-title":"Nat Rev Immunol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.581820\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T09:34:58Z","timestamp":1606296898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.581820\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,25]]},"references-count":23,"alternative-id":["10.3389\/fmed.2020.581820"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.581820","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2020,11,25]]},"article-number":"581820"}}